Arvinas (ARVN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $2.58
- Estimate
- -$0.29
- Surprise
- +1000.0%
- Revenue (period 2026-06-30)
- $249.7M
- Score at report (before → after)
- 5.0 → 6.4/10
Revenue source: xbrl.
How the report landed
Arvinas (ARVN) beat the -$0.29 estimate with adjusted EPS of $2.58 — a large 1000.0% upside surprise. TrendMatrix's engine moved from Sell (5.0/10) to Hold at 6.4/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ARVN Sell at 5.6/10.
3 of the last 4 quarters beat the estimate; this quarter's +1000.0% surprise compares with a +234.6% four-quarter average. Next scheduled report: 2027-02-23.
What argues against it
- Quality below floor (2.8 < 4.0)
- Value-trap signals (2/5): Margin compression (op margin -3.0%), High leverage (D/E 27.9)
- Momentum score 3.0/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $6.77
- Price target
- $12.18
- Stop
- $6.30
- Upside to target
- +79.9%
- Reward-to-risk
- 5.8:1
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
ARVN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $446.6M
- P/E (fwd)
- -2.1
- 52-week range
- $6.33–$14.51
- Off 52-week high
- 53.3%
- RSI (14)
- 40
- Volume vs avg
- 1.38×
- Score today
- 5.6/10